Therapy Areas: Oncology
Karyopharm Therapeutics names new CCO
11 January 2022 -

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a US-based commercial-stage pharmaceutical company, announced on Monday that it has promoted Sohanya Cheng to chief commercial officer.

In the new role, Cheng will be responsible for heading the firm's commercial strategy and operations, including the continued commercialization of XPOVIO (selinexor).

Cheng joined the company as senior vice president of Sales and Commercial Operations. She has 18 years of biopharmaceutical commercialisation and research experience, predominately in oncology. She has held the position of vice president, head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals. She has spent more than 10 years at Amgen.



Related Headlines